Taiwanese flat-panel TV maker Amtran Technology Co Ltd (瑞軒) said yesterday its affiliate, Vizio Inc, had filed an anti-trust and unfair competition lawsuit against its Japanese rival, Funai Electronics Co, in the US.
The latest legal action by Vizio followed a ruling by the US International Trade Commission’s that invalidated a related patent that Funai had attempted to enforce against Vizio and to review a judge’s prior decision that Vizio had infringed on part of US Patent No. 6,115,074.
Irvine, California-based Vizio alleged that Funai, “acting alone and in concert with others, unlawfully restrained trade and monopolized the market for the licensing of technology used to interpret and retrieve information from a digital television broadcast signal, as well as the market for digital television sets and receivers,” Amtran said, citing Vizio.
Amtran has a 23 percent stake in Vizio and makes flat-screen TVs for the US’s third-largest liquid-crystal-display (LCD) panel TV maker.
“The company will safeguard the company’s legal rights and seek any possible means to protect the company’s interest,” Amtran said in a filing to the Taiwan Stock Exchange yesterday.
Vizio expanded its share of the US LCD market by volume to 12.8 percent in the fourth quarter of last year, up from the third quarter’s 8.4 percent, behind Sony Corp and top-brand Samsung Electronics Co, market researcher DisplaySearch’s latest tallies showed.
Vizio filed the antitrust and unfair competition lawsuit in the US District Court, Central District of California, against Funai and related components, a company statement released earlier this month on its Web site said.
“VIZIO, as America’s HDTV Company, has been instrumental in making high quality flat panel TVs more affordable for Americans. Especially in light of the nation’s digital TV transition, we won’t allow a foreign competitor to divert us from our mission to bring affordable high quality HDTVs to millions of Americans,” Vizio co-founder Laynie Newsome said in a statement.
Amtran jumped 3.2 percent to NT$11.25 yesterday, outperforming the TAIEX’s 0.9 percent rise.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and
‘IMPORTANT MILESTONE’: The firm expects to launch the generic of Revlimid in the US after March 2022. It has already launched the product in some European countries Lotus Pharmaceutical Co Ltd (美時化學製藥) has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for lenalidomide, the company said in a statement on Friday. The ANDA approval is for 2.5mg, 5mg, 10mg, 20mg and 25mg capsules of lenalidomide, which is a generic version of blood cancer drug Revlimid developed by Celgene Corp. It is the first product fully developed and manufactured in Lotus’ facilities in Taiwan. Lotus expects to launch the product in the US — based on its patent litigation settlement with Celgene last year — some time after March